EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kuwanon A Targeted YWHAB in Hepatocellular Carcinoma Cells to Inhibit the Raf/MEK/ERK Signaling Pathway

Jingyang Xu, Hongbo Chang, Yongzhao Wang, Yi Du, Liping Zhong, Hongjuan Cui iD

Cells · 23.09.2025 · 14 (19) · 1487

DOI: 10.3390/cells14191487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 23.09.2025. Verfasst von Jingyang Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing 400715, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MAP Kinase Signaling System, raf Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing, Fundamental Research Funds for the Central Universities, Science and Technology Major Project of Guangxi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, and the lung is one of the most frequent metastatic sites for HCC. In this study, we aimed to identify a mild active substance in Morus alba L. that can inhibit the pulmonary metastasis of HCC and reduce the drug resistance of clinical therapies. Further deepen the understanding of the anti-cancer functions of the mulberry active substances. In this study, we have screened and identified a flavonoid compound extracted from the root bark of the Morus alba L. named Kuwanon A (KA). Our research demonstrated that KA directly targeted the YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) and mediated its dimer dissociation. Thereby inhibiting the MAPK pathway and affecting downstream biological functions, including cell cycle arrest and migration/invasion inhibition. The experiment results proved that KA could inhibit the proliferation and metastasis of highly metastatic HCC cells both in vitro and in vivo. Additionally, when KA was combined with the clinical drug sorafenib, it exhibited a synergistic effect in inhibiting HCC cell proliferation, migration, and invasion. In conclusion, KA demonstrated a favorable anti-tumor effect in HCC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMAP Kinase Signaling Systemraf KinasesFlavonoidsHumansAnimalsCell ProliferationCell Line, TumorCell MovementMiceMice, NudeSorafenibMice, Inbred BALB CMorusFlavones

Stichwörter der Autor:innen

Kuwanon AYWHABchemosensitivityhepatocellular carcinoma

Substanzen

raf KinasesSorafenibFlavonoidskuwanon AFlavones

Autor:innen und Institutionen

  • State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing 400715, China.
  • Jinfeng Laboratory, Chongqing 401329, China.
  • State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.

ORCID-Profile: Hongjuan Cui

Förderung

  • Natural Science Foundation of Chongqing
  • Fundamental Research Funds for the Central Universities
  • Science and Technology Major Project of Guangxi

Zitieren

APA

Xu, J., Chang, H., Wang, Y., Du, Y., Zhong, L., & Cui, H. (2025). Kuwanon A Targeted YWHAB in Hepatocellular Carcinoma Cells to Inhibit the Raf/MEK/ERK Signaling Pathway. Cells, 14(19), 1487. https://doi.org/10.3390/cells14191487

Vancouver

Xu J, Chang H, Wang Y, Du Y, Zhong L, Cui H. Kuwanon A Targeted YWHAB in Hepatocellular Carcinoma Cells to Inhibit the Raf/MEK/ERK Signaling Pathway. Cells. 2025;14(19):1487. doi:10.3390/cells14191487

BibTeX
@article{Xu2025,
  author = {Xu, Jingyang and Chang, Hongbo and Wang, Yongzhao and Du, Yi and Zhong, Liping and Cui, Hongjuan},
  title = {Kuwanon A Targeted YWHAB in Hepatocellular Carcinoma Cells to Inhibit the Raf/MEK/ERK Signaling Pathway},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {19},
  pages = {1487},
  doi = {10.3390/cells14191487}
}
Kostenlos starten →